002923.SZ
润都股份
SZSE · Healthcare · C 制造业 · CN
CNY 10.88
−3.55%Aug 31, 2026, 08:07 UTC
Rundu Pharmaceutical received approval from the National Medical Products Administration for its Levamlodipine Besylate API, used to treat hypertension and angina pectoris.
Source:Aug 31, 2026, 08:03 UTC
Rundu Pharmaceutical received approval from China's National Medical Products Administration for its chemical API (levamlodipine besylate) marketing application in August 2026.
Source:Aug 3, 2026, 08:27 UTC
Rundu shares' diclofenac sodium sustained-release tablets (75mg and 100mg) are provisionally selected in the 12th national drug centralized procurement, with the procurement period running until December 31, 2029.
Source:Jul 21, 2026, 08:44 UTC
Rundu Pharmaceutical received an approval notice from the National Medical Products Administration for the listing application of lanthanum carbonate chemical raw material drug.
Source:Jul 6, 2026, 10:38 UTC
Lixi, the controlling shareholder of Rundo Shares, reduced his shareholding through centralized bidding and block trading from October 9, 2025 to July 3, 2026, decreasing the combined shareholding of Lixi and Chen Xinmin from 60% to 55%.
Source: